Trial Profile
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Docetaxel (Primary) ; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2019 Planned End Date changed from 31 Aug 2024 to 31 Dec 2019.